These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 32758152)

  • 1. A randomized crossover trial to assess therapeutic efficacy and cost reduction of acid ursodeoxycholic manufactured by the university hospital for the treatment of primary biliary cholangitis.
    Nakano LA; Cançado ELR; Chaves CE; Madeira MCV; Katayose JT; Nabeshima MA; Fossaluza V; Uhrigshardt GG; Liting Z; Pinto VB; Carrilho FJ; Ono SK
    BMC Gastroenterol; 2020 Aug; 20(1):253. PubMed ID: 32758152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased infiltration of CD4
    Yu K; Li P; Xu T; Xu J; Wang K; Chai J; Zhao D; Liu Y; Wang Y; Ma J; Fan L; Guo S; Li Z; Li M; Wang Z
    Pathol Res Pract; 2021 Jan; 217():153291. PubMed ID: 33249399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study.
    Wunsch E; Raszeja-Wyszomirska J; Barbier O; Milkiewicz M; Krawczyk M; Milkiewicz P
    J Gastrointestin Liver Dis; 2018 Sep; 27(3):273-279. PubMed ID: 30240471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA.
    Hirschfield GM; Beuers U; Kupcinskas L; Ott P; Bergquist A; Färkkilä M; Manns MP; Parés A; Spengler U; Stiess M; Greinwald R; Pröls M; Wendum D; Drebber U; Poupon R
    J Hepatol; 2021 Feb; 74(2):321-329. PubMed ID: 32950590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Worse Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients with Autoimmune Hepatitis Features.
    Wen M; Men R; Fan X; Shen Y; Ni P; Hu Z; Yang L
    Dig Dis; 2021; 39(4):366-374. PubMed ID: 33238269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Response to Primary Biliary Cholangitis Treatment: Influencing Factors and the Role in Prognosis Prediction].
    Liu Y; Fan X; Shen Y; Men R; Guo Y; Yang L
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Sep; 54(5):930-936. PubMed ID: 37866948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.
    Hegade VS; Khanna A; Walker LJ; Wong LL; Dyson JK; Jones DEJ
    Dig Dis Sci; 2016 Oct; 61(10):3037-3044. PubMed ID: 27435324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.
    Harms MH; van Buuren HR; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Hirschfield GM; Parés A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Lammers WJ; Hansen BE; van der Meer AJ
    J Hepatol; 2019 Aug; 71(2):357-365. PubMed ID: 30980847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study.
    Jones DEJ; Wetten A; Barron-Millar B; Ogle L; Mells G; Flack S; Sandford R; Kirby J; Palmer J; Brotherston S; Jopson L; Brain J; Smith GR; Rushton S; Jones R; Rushbrook S; Thorburn D; Ryder SD; Hirschfield G; ; Dyson JK
    EBioMedicine; 2022 Jun; 80():104068. PubMed ID: 35609437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant Sjögren's Syndrome Was Not Associated with a Poorer Response or Outcomes in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis.
    Ni P; Men R; Shen M; Wang T; Huang C; Fan X; Yang L
    Can J Gastroenterol Hepatol; 2019; 2019():7396870. PubMed ID: 31275901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update.
    Bowlus CL; Kenney JT; Rice G; Navarro R
    J Manag Care Spec Pharm; 2016 Oct; 22(10-a-s Suppl):S3-S15. PubMed ID: 27700211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High neutrophil-lymphocyte ratio indicates a worse response to ursodeoxycholic acid in primary biliary cholangitis: a retrospective cohort study.
    Zhu H; Zheng M; He H; Lei H; Tai W; Yang J
    BMC Gastroenterol; 2023 Nov; 23(1):400. PubMed ID: 37978445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RANK/RANKL Acts as a Protective Factor by Targeting Cholangiocytes in Primary Biliary Cholangitis.
    Hao YL; Bian ZL; Ju LL; Liu Y; Qin G
    Dig Dis Sci; 2020 Feb; 65(2):470-479. PubMed ID: 31377883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.
    Carbone M; Nardi A; Flack S; Carpino G; Varvaropoulou N; Gavrila C; Spicer A; Badrock J; Bernuzzi F; Cardinale V; Ainsworth HF; Heneghan MA; Thorburn D; Bathgate A; Jones R; Neuberger JM; Battezzati PM; Zuin M; Taylor-Robinson S; Donato MF; Kirby J; Mitchell-Thain R; Floreani A; Sampaziotis F; Muratori L; Alvaro D; Marzioni M; Miele L; Marra F; Giannini E; Gaudio E; Ronca V; Bonato G; Cristoferi L; Malinverno F; Gerussi A; Stocken DD; Cordell HJ; Hirschfield GM; Alexander GJ; Sandford RN; Jones DE; Invernizzi P; Mells GF;
    Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):626-634. PubMed ID: 30017646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of primary biliary cholangitis with ursodeoxycholic acid, prednisolone and immunosuppressants in patients not responding to ursodeoxycholic acid alone and the prognostic indicators.
    Qian JD; Yao TT; Wang Y; Wang GQ
    Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):874-884. PubMed ID: 32305248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Fenofibrate in Treatment-Naive Patients With Primary Biliary Cholangitis: A Randomized Clinical Trial.
    Liu Y; Guo G; Zheng L; Sun R; Wang X; Deng J; Jia G; Yang C; Cui L; Guo C; Shang Y; Han Y
    Am J Gastroenterol; 2023 Nov; 118(11):1973-1979. PubMed ID: 36892506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis].
    Yuan Z; Jia G; Han Y
    Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):73-76. PubMed ID: 30685931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninvasive prediction of insufficient biochemical response after ursodeoxycholic acid treatment in patients with primary biliary cholangitis based on pretreatment nonenhanced MRI.
    Zhang Y; Fan X; Song B; Liu Y; Chen Y; Zheng T; Guo Y; Duan T; Huang Z; Yang L
    Eur Radiol; 2024 Feb; 34(2):1268-1279. PubMed ID: 37581659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case-control study on prednisolone combined with ursodeoxycholic acid and azathioprine in pure primary biliary cirrhosis with high levels of immunoglobulin G and transaminases: efficacy and safety analysis.
    Fang YQ; Lv DX; Jia W; Li J; Deng YQ; Wang Y; Yu M; Wang GQ
    Medicine (Baltimore); 2014 Oct; 93(20):e104. PubMed ID: 25365404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.